These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 20940135)
1. The fabulous neuroprotection of selegiline: memoir and prospectus. Landau WM J Child Neurol; 2010 Oct; 25(10):1302-4. PubMed ID: 20940135 [No Abstract] [Full Text] [Related]
2. DATATOP-study: significance of its results in the treatment of Parkinson's disease. Schneider E J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074 [TBL] [Abstract][Full Text] [Related]
3. [Drug therapy of Parkinson's disease]. Myllylä V Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076 [No Abstract] [Full Text] [Related]
4. [What strategies are recommended for early stage disease? Other treatments]. Damier P Rev Neurol (Paris); 2000; 156 Suppl 2 Pt 2():105-8. PubMed ID: 10916044 [No Abstract] [Full Text] [Related]
10. Neuroprotection for Parkinson's disease: prospects and promises. Olanow CW; Schapira AH; Agid Y Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093 [No Abstract] [Full Text] [Related]
11. Transdermal selegiline (Emsam). Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292 [No Abstract] [Full Text] [Related]
12. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Chen JJ; Swope DM; Dashtipour K Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186 [TBL] [Abstract][Full Text] [Related]
13. Neuroprotection by selegiline and other MAO inhibitors. Stern G J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613 [TBL] [Abstract][Full Text] [Related]
15. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease. Jenner P Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581 [No Abstract] [Full Text] [Related]
16. Current status of selegiline as a neuroprotective agent in Parkinson's disease. Olanow CW; Mytilineou C; Tatton W Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720 [No Abstract] [Full Text] [Related]
17. MAO-B inhibitor know-how: back to the pharm. Lewitt PA Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057 [No Abstract] [Full Text] [Related]
18. Selegiline for Parkinson's disease. Calesnick B Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624 [TBL] [Abstract][Full Text] [Related]
19. Preclinical versus clinical neuroprotection. Grünblatt E; Schlösser R; Gerlach M; Riederer P Adv Neurol; 2003; 91():309-28. PubMed ID: 12442689 [No Abstract] [Full Text] [Related]
20. [Use of iumeks in the combined therapy of parkinsonism patients ]. Man'kovskiĭ NB; Karaban' IN; Mialovitskaia EA Vrach Delo; 1987 Aug; (8):100-2. PubMed ID: 3120415 [No Abstract] [Full Text] [Related] [Next] [New Search]